Therapeutic Potential of Proanthocyanidins in Ulcerative Colitis in Remission
نویسندگان
چکیده
منابع مشابه
Review article: defining remission in ulcerative colitis.
BACKGROUND There is no international agreement on scoring systems used to measure disease activity in ulcerative colitis, nor is there a validated definition for disease remission. AIM To review the principles and components for defining remission in ulcerative colitis and propose a definition that will help improve patient outcomes. METHODS A review of current standards of remission from t...
متن کاملPulmonary function in ulcerative colitis
Abstract Background: Pulmonary involvement in ulcerative colitis (UC) is thought to be rare. There is not a definite document about the question that "Is the lung a target organ in inflammatory bowel disease?" The aim of the present study is to compare lung function between cases with UC and healthy controls. This study will also be of interest about searching the outbreak of pulmonary functio...
متن کاملSymptoms of irritable bowel syndrome in ulcerative colitis in remission.
The prevalence of symptoms suggestive of a motility disturbance similar to the irritable bowel syndrome was investigated in 98 patients with ulcerative colitis in remission, and a similar number of age- and sex-matched healthy controls. Thirty-three per cent of patients compared with 7% of controls fulfilled the criteria for such a syndrome (p<0.01). Contrary to expectations these symptoms were...
متن کاملAdrenomedullin as a Potential Therapeutic Agent for Refractory Ulcerative Colitis
K. Kitamura , M.D., Ph.D. (*) • S. Ashizuka • H. Inatsu • T. Kita Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine , University of Miyazaki , 5200 Kihara, Kiyotake , Miyazaki City , Miyazaki 889-1692 , Japan e-mail: [email protected] Abstract Adrenomedullin (AM) was originally isolated from human pheochromocytoma as a biologically active pe...
متن کاملOptimum dose of olsalazine for maintaining remission in ulcerative colitis.
To evaluate the optimum dose of olsalazine for maintaining remission in ulcerative colitis, 198 patients in remission for more than three months were randomly assigned to receive 0.5 g, 1.0 g, or 2.0 g/day for 12 months. A dose-ranging effect was detected in the per protocol analysis, with remission rates of 60% (0.5 g), 70% (1.0 g), and 78% (2.0 g) (p = 0.03, trend in proportions). The higher ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Medicine
سال: 2020
ISSN: 2077-0383
DOI: 10.3390/jcm9030771